Atlas Trials

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Clinical trial NCT04531046 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04531046
Sponsor
The Lymphoma Academic Research Organisation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
B-Cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Start date
2021-03-10
Primary completion
2022-04-19
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.